Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Other: AfliberceptOther: RanibizumabOther: Bevacizumab
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 331541
- Registration Number
- NCT05110209
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT05110196
- Locations
- 🇮🇳
Novartis Investigative Site, Puducherry, India
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
- Conditions
- Advanced Hormone Receptor Positive (HR+) Breast Cancer
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05108740
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05109728
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Col Uni Med Center New York Presby, New York, New York, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Managed Access Programs for LDK378, Ceritinib
- Conditions
- Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05100134
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1614719
- Registration Number
- NCT05096039
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42269
- Registration Number
- NCT05096143
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Disease modifying treatment (DMT)
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05090371
- Locations
- 🇺🇸
Palmetto Clinical Research, Summerville, South Carolina, United States
🇺🇸Sibyl Wray MD Neurology PC, Knoxville, Tennessee, United States
🇺🇸Alabama Neurology Associates PC, Birmingham, Alabama, United States
Characterizing the Use of Ofatumumab in a Real World Setting
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Other: ofatumumab
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT05090033
- Locations
- 🇦🇺
Novartis Investigative Site, St Leonards, Australia
Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
- Conditions
- Type 2 Spinal Muscular Atrophy
- Interventions
- Genetic: OAV101Procedure: Sham control
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT05089656
- Locations
- 🇻🇳
National Children's Hospital, Hanoi, Vietnam
🇺🇸Connecticut Children's Medical Center, Farmington, Connecticut, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States